a public good project by the
Synthesis
Company
of California

© 2026

Angelo J. Trapani | doi.page

0 works0 citations0 h-index

Angelo J. Trapani

Novartis (United States)(US)

Publications by Year

Research Areas

Peptidase Inhibition and Analysis, Nitric Oxide and Endothelin Effects, Diabetes Treatment and Management, Renin-Angiotensin System Studies, Heart Failure Treatment and Management

Most-Cited Works

→ Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial(2012)899 cited
→ Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program(2012)424 cited
→ Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension(2011)209 cited
→ Potent and Selective Non-Peptidic Inhibitors of Endothelin-Converting Enzyme-1 with Sustained Duration of Action(2000)100 cited
→ Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors(1995)81 cited
→ N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors(1994)79 cited

→ Pharmacological Profile of a Non-peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-Converting Enzyme(1994)

78 cited

→ Are increases in cyclic GMP levels responsible for the negative inotropic effects of acetylcholine in the heart?(1977)77 cited

→ Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo(1989)72 cited

→ Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial(2022)71 cited